Joinn Laboratories(China)Co.,Ltd.

Equities

603127

CNE100002W27

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 27/06/2024 BST			5-day change	1st Jan Change
13.27 ^CNY	-1.19%		-6.55%	-44.03%

06-20	Joinn Laboratories Co.,Ltd. Approves Final Cash Dividend for the Year Ended December 31, 2023, Payable on 31 July 2024	CI
04-30	Nomura Adjusts Joinn Laboratories’ Prive Target to 17.37 Yuan From 21.01 Yuan, Keeps at Neutral	MT

Joinn Laboratories Co.,Ltd. Approves Final Cash Dividend for the Year Ended December 31, 2023, Payable on 31 July 2024

June 20, 2024 at 03:44 pm

Joinn Laboratories(China)Co.,Ltd. approved final ordinary dividend in cash of RMB 0.16 per share for the year ended December 31, 2023 Ex-dividend date is 28 June 2024. Record date is 05 July 2024. Payment date is 31 July 2024.

Date of shareholders' approval is 20 June 2024.

Latest news about Joinn Laboratories(China)Co.,Ltd.

Joinn Laboratories Co.,Ltd. Approves Final Cash Dividend for the Year Ended December 31, 2023, Payable on 31 July 2024	06-20	CI
Nomura Adjusts Joinn Laboratories’ Prive Target to 17.37 Yuan From 21.01 Yuan, Keeps at Neutral	04-30	MT
Nomura Adjusts Joinn Laboratories’ Price Target to HK$10.41 From HK$12.60, Keeps at Neutral	04-30	MT
Joinn Laboratories(China)Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Tranche Update on Joinn Laboratories(China)Co.,Ltd.'s Equity Buyback Plan announced on April 3, 2024.	04-02	CI
Joinn Laboratories(China)Co.,Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	04-02	CI
Joinn Laboratories' Profit Slumps 63% in 2023, Misses Estimates	04-01	MT
Joinn Laboratories(China)Co.,Ltd. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 31 July 2024	03-28	CI
Joinn Laboratories(China)Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Joinn Laboratories(China)Co.,Ltd. authorizes a Buyback Plan.	03-27	CI
MSCI to Remove 74 Companies From China Onshore Index Including China Southern Airlines, Weibo, Greentown China	02-14	MT
Joinn Laboratories’ Actual Controller Receives Warning From Beijing Securities Regulator	02-13	MT
Nomura Downgrades Joinn Laboratories (China) to Neutral From Buy, Adjusts Price Target to HK$12.60 From HK$20.93	01-24	MT
Nomura Downgrades Joinn Laboratories (China) to Neutral From Buy, Adjusts Price Target to 21.01 Yuan From 35 Yuan	01-24	MT
Joinn Laboratories' 2023 Attributable Profit Seen to Decline; Shanghai Shares Fall 5%	01-24	MT
Joinn Laboratories(China)Co.,Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023	01-23	CI
Joinn Laboratories' Q3 Profit Falls 9%	31/10/23	MT
Joinn Laboratories(China)Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23	CI
Nomura Adjusts Joinn Laboratories' Price Target to 35 Yuan From 34.52 Yuan, Keeps at Buy	25/10/23	MT
Nomura Adjusts Joinn Laboratories (China)'s Price Target to HK$20.93 From HK$20.64, Keeps at Buy	25/10/23	MT
Nomura Adjusts Joinn Laboratories China's Price Target to HK$20.64 From HK$31.23, Keeps at Buy	01/09/23	MT
Nomura Adjusts Joinn Laboratories China's Price Target to 34.52 Yuan From 49.19 Yuan, Keeps at Buy	01/09/23	MT
Joinn Laboratories' H1 Attributable Profit Falls 76%	31/08/23	MT
Joinn Laboratories(China)Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	30/08/23	CI
Joinn Laboratories (China) Expects Up to 80% Decline in First-Half Profit	19/07/23	MT

Chart Joinn Laboratories(China)Co.,Ltd.

Duration

Period

More charts

Company Profile

Joinn Laboratories China Co Ltd is a China-based company primarily engaged in the pharmacology and toxicology research of new drugs. Non-clinical research services include drug safety evaluation, pharmacokinetic research as well as pharmacological and pharmacodynamic research. Clinical trials and related services include clinical contract research organization services, phase I clinical research collaboration unit (CRU), and bioanalysis services. Experimental model business mainly includes rodents and non-human primates. The Company conducts its businesses both in the domestic market and overseas markets.

Sector

Biotechnology & Medical Research

Calendar

26/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Joinn Laboratories(China)Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

13.27 CNY

Average target price

18.73 CNY

Spread / Average Target

+41.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
JOINN LABORATORIES(CHINA)CO.,LTD.	-44.03%	1.26B
MODERNA, INC.	+19.41%	45.51B
IQVIA HOLDINGS INC.	-8.62%	38.52B
LONZA GROUP AG	+39.19%	38.13B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
CELLTRION, INC.	-13.50%	26.03B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B

Other Biotechnology & Medical Research